Nilotinib as first-line therapy for chronic myeloid leukemia.
Indian J Cancer
; 2011 Oct-Dec; 48(4): 438-445
Article
em En
| IMSEAR
| ID: sea-144524
ABSTRACT
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
Palavras-chave
Texto completo:
1
Índice:
IMSEAR
Assunto principal:
Piperazinas
/
Pirimidinas
/
Proteínas Tirosina Quinases
/
Humanos
/
Resistência a Medicamentos
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Intervalo Livre de Doença
/
Terapia de Alvo Molecular
/
Animais
/
Antineoplásicos
Idioma:
En
Revista:
Indian J Cancer
Ano de publicação:
2011
Tipo de documento:
Article